Dr Reddys Laboratories News

Sun Pharmaceutical Industries Ltd, India's top drugmaker by market capitalisation, reported a better-than-expected 91 percent rise in December quarter net profit on robust sales by Israeli unit Taro Pharmaceutical Industries.

Dr Lorrise Williamson tends to a patient during the Shipping Association of Jamaica's health fair held in partnership with the Rotary Club of Liguanea Plains, the Rotary Club of St Andrew North, Dr Reddy's Laboratories Limited, Maritime and Transport Services and SECURIPRO on January 21 at St Stephen's United Church, Union Square.

Dr. Reddy's Laboratories Limited was downgraded by research analysts at Credit Suisse from an "outperform" rating to a "neutral" rating in a report issued on Tuesday.

The 10-second takeaway For the quarter ended Dec. 31 , Dr. Reddy's Laboratories beat expectations on revenues and beat expectations on earnings per share.

Dr. Reddy's Laboratories reported higher-than-expected 3QFY2012 results. Net sales increased by 45.9% yoy, led by 57% yoy and 12% yoy growth across the global generics and proprietary products businesses, respectively.

Fondaparinux is a generic version of GlaxoSmithKline's Arixtra, a synthetic anticoagulant mainly used for the prevention of deep vein thrombosis.

The Indian pharmaceutical industry is gaining steam, and the results are reflected in the S&P CNX Nifty, the leading index for large companies on India's National Stock Exchange.

Gunupati Venkateswara Prasad - Executive Vice Chairman, Chief Executive Officer, Member of Management Council, Chairman of Investment Committee, Member of Strategy Committee, Member of Shareholders Grievance Committee and Member of Management Committee Kallam Satish Reddy - Managing Director, Chief Operating Officer, Executive Director, Member of ... (more)

Dr Reddy's Laboratories , India's No. 2 drugmaker by sales, reported a forecast-beating 88 percent jump in quarterly net profit as sales in its key U.S. market more than doubled.

Dr. Reddy's Laboratories Ltd. today announced its unaudited consolidated financial results for the quarter ended December 31, 2011 under International Financial Reporting Standards .

Mumbai, Feb 3 : Dr Reddy's Laboratories, an integrated global pharmaceutical company, today said its consolidated net profit surged by 87.80 per cent to Rs 512.96 crore for the quarter ended December 31, 2011 as compared to Rs 273.14 crore for the quarter ended December 31, 2010.

New Delhi: Drug firm Dr Reddy's Laboratories today said its consolidated net profit rose by 87.80 per cent to Rs 512.96 crore in the third quarter ended December 31, 2011 vis-a-vis the corresponding year-ago period.

Diversified healthcare giant Novartis reported impressive 2011 results in January 2012.

HOTBEDS Regional News US & Canada Biotech Bay Biotech Beach Genetown Pharm Country BioCapital BioMidwest Bio NC BioForest Southern Pharm BioCanada East US Device Europe Asia HYDERABAD, India-- --Dr. Reddy's Laboratories wishes to clarify that the media reports highlighting its troubles with the US health authorities related to certain promotional ... (more)

New Delhi: Anji Reddy-led Dr Reddy's Laboratories fell on a report that the pharmaceutical company has run into trouble with the U.S. health authorities for not highlighting important risk information on a promotional website for injectable generic fondaparinux sodium, a drug that it launched in the U.S. market recently, two dealers said.

HYDERABAD: Is Kallam Anji Reddy, chairman of Dr Reddy's Laboratories Ltd , easing his grip on the company he founded way back in 1984? If the latest shareholding structure is anything to go by, Reddy owns no more stake in DRL in his individual capacity.